Second-line tisagenlecleucel does not improve outcomes in B-cell lymphoma
Physician's Weekly,
1. Patients with B-cell non-Hodgkin’s lymphoma receiving tisagenlecleucel did not show delayed lymphoma progression compared to…
1. Patients with B-cell non-Hodgkin’s lymphoma receiving tisagenlecleucel did not show delayed lymphoma progression compared to…
Madrigal et al PNAS Feb 2022 Figure 2 Way back in 2009 I remember the first time my sales manager at RainDance Technologies…
Study suggests results could change treatment paradigm for this patient…
Management of the cytokine release syndrome seen in association with CAR T-cell therapy best done with early introduction of IL-6…
CAR-T therapies have been a hot area right now. Pharmaceutical companies and biotechnology companies are all trying to jump…
A profile of CAR-T therapy for patients with a form of lymphoma, Richard Maziarz, M.D., says that with this new treatment, “We’re…
The true extent of the opioid prescribing rise in the UK
The post CAR T-cell therapy is ground-breaking, expensive and hard to deliver. Is Canada ready for it? appeared first on…
Richard T. Maziarz, MD© ASH/Luke Franke…
OHSU physician-researcher presents updated gene transfer therapy data at conference, publishes study results in The New England…
Alex Nowbar reviews the latest research from the top medical…
New longer-term data on CAR T cells from pivotal clinical trials show durable responses, with some patients remaining in…
Research led by Richard Maziarz, M.D., on the durability of gene transfer therapy treatment for patients with a form of…